Literature DB >> 24732011

Possible leap ahead in filovirus therapeutics.

Darryl Falzarano1, Heinz Feldmann1.   

Abstract

In a recent study published in Nature, Warren et al. describe the generation of a novel synthetic adenosine analogue, BCX4430, a synthetic drug-like small molecule that provides protection from Ebola and Marburg virus infection in animal models.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24732011      PMCID： PMC4042172          DOI： 10.1038/cr.2014.49

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  11 in total

1.  Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Dana L Swenson; Kelly S Donner; Sean A Van Tongeren; Nicole L Garza; Lian Dong; Dan V Mourich; Stacy Crumley; Donald K Nichols; Patrick L Iversen; Sina Bavari
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

2.  Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.

Authors:  Xiangguo Qiu; Jonathan Audet; Gary Wong; Stephane Pillet; Alexander Bello; Teresa Cabral; Jim E Strong; Frank Plummer; Cindy R Corbett; Judie B Alimonti; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

3.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

Authors:  John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

4.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

5.  Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.

Authors:  Kathleen M Daddario-DiCaprio; Thomas W Geisbert; Ute Ströher; Joan B Geisbert; Allen Grolla; Elizabeth A Fritz; Lisa Fernando; Elliott Kagan; Peter B Jahrling; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

6.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Authors:  Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

7.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

8.  Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.

Authors:  Lisa E Hensley; Edward L Stevens; S Betty Yan; Joan B Geisbert; William L Macias; Tom Larsen; Kathleen M Daddario-DiCaprio; Gail H Cassell; Peter B Jahrling; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

9.  Effective post-exposure treatment of Ebola infection.

Authors:  Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

10.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors:  Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321
View more
  5 in total

1.  Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes.

Authors:  Thomas Hoenen; Ari Watt; Anita Mora; Heinz Feldmann
Journal:  J Vis Exp       Date:  2014-09-27       Impact factor: 1.355

2.  Complete genome sequences of three ebola virus isolates from the 2014 outbreak in west Africa.

Authors:  T Hoenen; A Groseth; F Feldmann; A Marzi; H Ebihara; G Kobinger; S Günther; H Feldmann
Journal:  Genome Announc       Date:  2014-12-18

3.  Ebola virus disease.

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-05       Impact factor: 2.471

4.  Ebola Virus Infection: Overview and Update on Prevention and Treatment.

Authors:  Miguel J Martínez; Abdulbaset M Salim; Juan C Hurtado; Paul E Kilgore
Journal:  Infect Dis Ther       Date:  2015-09-12

Review 5.  Ebola virus (EBOV) infection: Therapeutic strategies.

Authors:  Erik De Clercq
Journal:  Biochem Pharmacol       Date:  2014-12-04       Impact factor: 5.858
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.